tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PVLA Stock Latest News

Palvella Therapeutics price target raised to $95 from $75 at H.C. Wainwright
The FlyPalvella Therapeutics price target raised to $95 from $75 at H.C. Wainwright
4d ago
PVLA
Palvella Expands QTORIN Gel Program for Rare Disease
PremiumCompany Announcements
Palvella Expands QTORIN Gel Program for Rare Disease
4d ago
8K
PVLA
Buy Rating for Palvella Therapeutics Driven by Strategic Expansion of QTORIN Rapamycin for Unmet CSA Treatment
PremiumRatings
Buy Rating for Palvella Therapeutics Driven by Strategic Expansion of QTORIN Rapamycin for Unmet CSA Treatment
4d ago
PVLA
Palvella Therapeutics: Expanding Market Potential with QTORIN 3.9% Rapamycin for Angiokeratomas
PremiumRatings
Palvella Therapeutics: Expanding Market Potential with QTORIN 3.9% Rapamycin for Angiokeratomas
4d ago
PVLA
Palvella Therapeutics price target raised to $80 from $60 at Stifel
PremiumThe Fly
Palvella Therapeutics price target raised to $80 from $60 at Stifel
4d ago
PVLA
Palvella Therapeutics expands QTORIN rapamycin development program
PremiumThe FlyPalvella Therapeutics expands QTORIN rapamycin development program
5d ago
PVLA
Buy Rating for Palvella Therapeutics: Innovative QTORIN 3.9% Rapamycin Gel Addresses Unmet Needs in Venous Malformations
Premium
Ratings
Buy Rating for Palvella Therapeutics: Innovative QTORIN 3.9% Rapamycin Gel Addresses Unmet Needs in Venous Malformations
11d ago
PVLA
Palvella Therapeutics announces publication of literature review of rapamycin
Premium
The Fly
Palvella Therapeutics announces publication of literature review of rapamycin
12d ago
PVLA
Optimistic Buy Rating for Palvella Therapeutics Amid Promising Trial Developments and Market Potential
PremiumRatings
Optimistic Buy Rating for Palvella Therapeutics Amid Promising Trial Developments and Market Potential
13d ago
PVLA
Palvella Therapeutics completes enrollment in Phase 2 TOIVA trial of QTORIN
PremiumThe Fly
Palvella Therapeutics completes enrollment in Phase 2 TOIVA trial of QTORIN
14d ago
PVLA
Palvella Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe Fly
Palvella Therapeutics initiated with an Outperform at Oppenheimer
20d ago
PVLA
Palvella Therapeutics Accelerates U.S. Launch Planning
PremiumCompany Announcements
Palvella Therapeutics Accelerates U.S. Launch Planning
26d ago
8K
PVLA
Palvella Therapeutics appoints Osborne as Chief Innovation Officer
PremiumThe FlyPalvella Therapeutics appoints Osborne as Chief Innovation Officer
26d ago
PVLA
Palvella Therapeutics price target raised to $66 from $52 at Canaccord
Premium
The Fly
Palvella Therapeutics price target raised to $66 from $52 at Canaccord
1M ago
PVLA
Palvella Therapeutics price target raised to $75 from $38 at H.C. Wainwright
Premium
The Fly
Palvella Therapeutics price target raised to $75 from $38 at H.C. Wainwright
1M ago
PVLA
Palvella Therapeutics Advances Rare Disease Pipeline
PremiumCompany Announcements
Palvella Therapeutics Advances Rare Disease Pipeline
1M ago
PVLA
Palvella Therapeutics price target raised to $60 from $50 at Chardan
PremiumThe Fly
Palvella Therapeutics price target raised to $60 from $50 at Chardan
2M ago
PVLA
Palvella Therapeutics: Strong Financial Position and Clinical Progress Justify Buy Rating with Raised Price Target
PremiumRatings
Palvella Therapeutics: Strong Financial Position and Clinical Progress Justify Buy Rating with Raised Price Target
2M ago
PVLA
Positive Buy Rating for Palvella Therapeutics Driven by Promising Phase 3 Trial Developments and Market Potential
PremiumRatings
Positive Buy Rating for Palvella Therapeutics Driven by Promising Phase 3 Trial Developments and Market Potential
2M ago
PVLA
Palvella Therapeutics price target raised to $60 from $45 at Stifel
PremiumThe FlyPalvella Therapeutics price target raised to $60 from $45 at Stifel
2M ago
PVLA
Palvella Completes Enrollment in Phase 3 SELVA Trial
Premium
Company Announcements
Palvella Completes Enrollment in Phase 3 SELVA Trial
2M ago
8K
PVLA
Palvella Therapeutics reports Q2 EPS (86c), consensus (77c)
Premium
The Fly
Palvella Therapeutics reports Q2 EPS (86c), consensus (77c)
2M ago
PVLA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >